Switching HIV treatment to a simpler daily pill
Part of Infections clinical trials.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HIV and are on treatment that includes a booster (ritonavir or cobicistat) plus at least 2 other drugs not in the NRTI class.
- You have changed HIV medications before because the virus was no longer controlled.
- Your viral load has been under 50 copies/mL for at least 6 months (one small spike up to 200 is okay).
- You are not infected with hepatitis B, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests switching your current HIV medicines to a once-daily pill combining doravirine, tenofovir, and lamivudine, specifically for people whose virus has a past M184V mutation but is now well controlled.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This study looks at switching your current HIV medication to a two-drug combination pill called dolutegravir/lamivudine (DTG/3TC). The goal is to see if this simpler regimen is safe and effective for people who are also on opioid agonist therapy. If you qualify, you may have the option to switch to a potentially easier HIV treatment while continuing your opioid therapy.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.